DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $601,189 | +21.5% | 2,423 | +17.6% | 0.05% | +30.0% |
Q2 2023 | $494,610 | -9.1% | 2,061 | -4.5% | 0.04% | -20.0% |
Q1 2023 | $544,037 | -4.6% | 2,159 | +0.5% | 0.05% | +2.0% |
Q4 2022 | $570,191 | +6.0% | 2,148 | +3.1% | 0.05% | -7.5% |
Q3 2022 | $538,000 | +1.9% | 2,084 | +0.0% | 0.05% | 0.0% |
Q2 2022 | $528,000 | +0.4% | 2,083 | +16.2% | 0.05% | +15.2% |
Q1 2022 | $526,000 | -10.5% | 1,793 | +0.3% | 0.05% | +7.0% |
Q4 2021 | $588,000 | +9.3% | 1,788 | +1.1% | 0.04% | -2.3% |
Q3 2021 | $538,000 | +13.5% | 1,768 | 0.0% | 0.04% | +12.8% |
Q2 2021 | $474,000 | -25.0% | 1,768 | -37.0% | 0.04% | -32.8% |
Q1 2021 | $632,000 | -1.2% | 2,808 | -2.5% | 0.06% | +5.5% |
Q4 2020 | $640,000 | -13.4% | 2,881 | -16.1% | 0.06% | -31.2% |
Q3 2020 | $739,000 | +87.1% | 3,434 | +53.6% | 0.08% | +73.9% |
Q2 2020 | $395,000 | -82.7% | 2,236 | -86.4% | 0.05% | -84.8% |
Q1 2020 | $2,278,000 | -30.8% | 16,458 | -23.3% | 0.30% | -3.2% |
Q4 2019 | $3,294,000 | +10.1% | 21,463 | +3.6% | 0.31% | +1.0% |
Q3 2019 | $2,993,000 | +123.2% | 20,721 | +120.9% | 0.31% | +70.7% |
Q2 2019 | $1,341,000 | -44.4% | 9,382 | -48.6% | 0.18% | +6.5% |
Q1 2019 | $2,410,000 | +13.7% | 18,260 | -11.2% | 0.17% | +10.4% |
Q4 2018 | $2,119,000 | – | 20,552 | – | 0.15% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |